Literature DB >> 17532712

Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules.

Alaa Ahmad1, William R Garnett.   

Abstract

Entities:  

Year:  2005        PMID： 17532712     DOI： 10.2165/00044011-200525100-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  23 in total

1.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

2.  Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

Authors:  R Riva; F Albani; G Ambrosetto; M Contin; P Cortelli; E Perucca; A Baruzzi
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

3.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

4.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Pharmacokinetic comparison of two carbamazepine slow-release formulations.

Authors:  P K Jensen; A Møller; L Gram; N O Jensen; M Dam
Journal:  Acta Neurol Scand       Date:  1990-08       Impact factor: 3.209

6.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

Authors:  T Tomson
Journal:  Arch Neurol       Date:  1984-08

7.  Controlled release carbamazepine: cognitive side effects in patients with epilepsy.

Authors:  A P Aldenkamp; W C Alpherts; M C Moerland; N Ottevanger; J A Van Parys
Journal:  Epilepsia       Date:  1987 Sep-Oct       Impact factor: 5.864

8.  Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.

Authors:  A D Miller; G L Krauss; F M Hamzeh
Journal:  Acta Neurol Scand       Date:  2004-06       Impact factor: 3.209

9.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

Review 10.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
View more
  3 in total

Review 1.  Extended-release formulations for the treatment of epilepsy.

Authors:  Meir Bialer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery.

Authors:  Nicola Di Trani; Antonia Silvestri; Antons Sizovs; Yu Wang; Donald R Erm; Danilo Demarchi; Xuewu Liu; Alessandro Grattoni
Journal:  Lab Chip       Date:  2020-05-05       Impact factor: 6.799

3.  Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.

Authors:  Nicola Di Trani; Hsuan-Chen Liu; Ruogu Qi; Dixita I Viswanath; Xuewu Liu; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Nanomedicine       Date:  2021-06-22       Impact factor: 6.096
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.